The Evolving Landscape of Oncology Drug Approvals: Breaking Down the FDA’s New Guidance With Harpreet Singh, MD

Understanding Accelerated Approvals and Confirmatory Trials

The accelerated approval pathway was introduced in the early 1990s in response to the HIV/AIDS crisis. It allows drugs targeting serious or life-threatening conditions to be approved based on early surrogate end points, such as tumor response rates in oncology. However, confirmatory trials must follow to verify long-term clinical benefit.

“The idea behind accelerated approval is that you could take an asset and conduct a trial with earlier or intermediate end point signals that the drug is effective, making it immediately available to patients,” explains Dr. Singh. “However, confirmatory trials are essential to mitigate risks and confirm the drug’s true impact.”

Over time, oncology drugs have dominated accelerated approvals, with about two-thirds of approvals in this pathway coming from cancer treatments.

Key Changes in the FDA’s New Guidance

The FDA’s new draft guidance requires that confirmatory trials be underway at the time of accelerated approval. This shift comes after concerns about “dangling accelerated approvals,” where companies fail to complete confirmatory trials, leaving drugs on the market without full validation of their benefits.

“This guidance stems from a Congressional act in 2023, giving the FDA the authority to withhold accelerated approval if the confirmatory trial is not underway,” notes Dr. Singh. “The goal is to prevent delays in verifying clinical benefit and ensure that patients receive truly effective therapies.”

The FDA is also emphasizing early and continuous engagement with sponsors to align on trial designs and confirmatory study expectations. While the guidance does not specify exact trial enrollment numbers, it stresses flexibility based on drug development challenges, especially for rare diseases.

Impact on Drug Development

For biotech companies, the new regulations pose both challenges and opportunities. Companies must now initiate confirmatory trials earlier, potentially requiring greater upfront capital. This shift increases risk at an earlier stage, as decisions on trial design and patient selection must be made with limited clinical data.

“Early-phase data is more critical than ever before,” says Dr. Singh. “Companies will need to maximize every data point, including pharmacokinetics, tumor expression, and translational biomarkers, to make informed decisions about trial design and regulatory strategy.”

Some companies may opt to bypass accelerated approval entirely and proceed directly to a traditional approval pathway, weighing the risks and benefits of different regulatory routes.

Strategies for Navigating the New Regulatory Landscape

To adapt to these regulatory changes, Dr. Singh recommends the following strategies for drug development companies and researchers:

• Engage early with the FDA: Frequent discussions can help align expectations and avoid regulatory roadblocks
• Optimize early-phase trials: Well-designed studies should capture comprehensive data to support both accelerated and confirmatory approvals
• Secure adequate funding: With higher upfront investment needs, biotech firms must plan financing strategies carefully to support dual trials
• Partner with experienced regulatory experts: Collaboration with clinical research organizations (CROs) and regulatory specialists can help navigate the evolving framework

“Getting a great thought partner and ensuring early-phase trials maximize data collection are key strategies to mitigate risk and improve success rates,” Dr. Singh advises.

Key Takeaways

• The FDA’s new guidance requires confirmatory trials to be underway at the time of accelerated approval
• The change aims to reduce delays in verifying clinical benefits and prevent dangling approvals
• Engaging with the FDA early, designing efficient early-phase trials, and partnering with regulatory experts will be critical for success
• While these regulatory shifts present challenges, they ultimately aim to ensure that patients receive safe and effective therapies with long-term benefits

About Dr. Singh

Harpreet Singh, MD, is the Chief Medical Officer at Precision for Medicine and a former Division Director of Oncology at the FDA, where she oversaw the development of multiple targeted therapies. Her extensive background also includes her role as Associate Director for Cancer in Older Adults and Special Populations at the FDA Oncology Center of Excellence, as well as a fellowship at the National Cancer Institute. Dr. Singh is recognized for her innovative contributions to drug development.